

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Karin KLOKKERS et al.

Serial No.:

10/019,121

Filed: May 16, 2003

For:

Matrix controlled transdermal system for stabile

derivatives of ace inhibitors

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

Examiner: Isis A D Ghali

Alexandria, VA 22313-1450, on

Group Art: 1615

November 21, 2006 (Date of Deposit)

Kent H. Cheng

Signature

November 21, 2006 Date of Signature

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

In compliance with the duty of disclosure under 37 C.F.R. §1.56 and in accordance with the practice under 37 C.F.R. §§1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents and the International Search Report are also enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final Action or the Notice of Allowance. 11/27/2006 TBESHAH1 00000038 032412 10019121 92 FC:1896

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentiability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

A check in the amount of \$180.00 in payment of the appropriate fee is enclosed. It is believed that no additional fees or charges are required at this time in connection with the present application. However, if any fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

> Respectfully submitted, COHEN, PONTANI, LIEBERMAN & PAVANE LLP

The PTO did not receive the following

listed Item(s) a chec

Kent H. Cheng

Reg. No. 33,849

551 Fifth Avenue, Suite 1210 New York, New York 10176

(212) 687-2770

Dated: November 21, 2006

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Q5, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for Form 1/1/9/PTO

NOV 2 7 2006	
INFORMATION DECLOSURE	
STATEMENT APPLICANT	

(Use as many sheets as necessary)

of

Sheet

Complete if Known			
Application Number	10/019,121		
Filing Date	May 16, 2003		
First Named Inventor	Karin KLOKKERS		
Art Unit	1615		
Examiner Name	Isis A D Ghali		
Attorney Docket Number	427101-34PUS		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number-Kind-Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-		1	

			FOREIGN F	PATENT DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³⁻ Number ⁴⁻ Kind-Code ⁵ (if known				
		EP 0439 430	7/31/1991	Ciba-Geigy AG		
		DE 198 21 788	12/2/1999	Schwarz Pharma AG		
		DE 298 23 343	08/26/1999	Schwarz Pharma AG		
		DE 197 28 517	01/07/1999	Schwarz Pharma AG		

Examiner	• 17	Date	
Signature		Considered	
- 18		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.